dbo:abstract
|
- Devimistat (INN; development code CPI-613) is an experimental drug being developed by Rafael Pharmaceuticals. It is being studied for the treatment of patients with metastatic pancreatic cancer and relapsed or refractory acute myeloid leukemia (AML). Devimistat's mechanism of action differs from other drugs, operating on the tricarboxylic acid cycle and inhibiting enzymes involved with cancer cell energy metabolism. A lipoic acid derivative different from standard cytotoxic chemotherapy, devimistat is currently being studied in combination with modified FOLFIRINOX to treat various solid tumors and heme malignancies. (en)
|
dbo:casNumber
| |
dbo:chEMBL
| |
dbo:drugbank
| |
dbo:fdaUniiCode
| |
dbo:pubchem
| |
dbo:thumbnail
| |
dbo:wikiPageID
| |
dbo:wikiPageLength
|
- 4157 (xsd:nonNegativeInteger)
|
dbo:wikiPageRevisionID
| |
dbo:wikiPageWikiLink
| |
dbp:c
| |
dbp:casNumber
| |
dbp:chembl
| |
dbp:chemspiderid
| |
dbp:drugbank
| |
dbp:h
| |
dbp:iupacName
| |
dbp:legalStatus
| |
dbp:o
| |
dbp:pubchem
| |
dbp:s
| |
dbp:smiles
|
- C1=CC=CCSCCCSCC2=CC=CC=C2 (en)
|
dbp:stdinchi
| |
dbp:stdinchikey
|
- ZYRLHJIMTROTBO-UHFFFAOYSA-N (en)
|
dbp:synonyms
| |
dbp:unii
| |
dbp:wikiPageUsesTemplate
| |
dcterms:subject
| |
rdf:type
| |
rdfs:comment
|
- Devimistat (INN; development code CPI-613) is an experimental drug being developed by Rafael Pharmaceuticals. It is being studied for the treatment of patients with metastatic pancreatic cancer and relapsed or refractory acute myeloid leukemia (AML). (en)
|
rdfs:label
| |
owl:sameAs
| |
prov:wasDerivedFrom
| |
foaf:depiction
| |
foaf:isPrimaryTopicOf
| |
is dbo:wikiPageRedirects
of | |
is dbo:wikiPageWikiLink
of | |
is foaf:primaryTopic
of | |